This osteoimmunological mechanism contributes to OP secondary to RA, as sustained Th-17/IL-17 activity promotes chronic inflammation, enhancing osteoclastogenesis and accelerating bone loss associated with RA. The gene discussed is IL17A; the disease is rheumatoid arthritis.